ELI LILLY & Co

Pharmaceutical Preparations·INDIANAPOLIS, IN·FY end 12/31·CIK 59478

CEO Pay Ratio

293:1

David A. Ricks

CEO Total Comp

$736.2K

David A. Ricks

Median Employee

$125,100

Revenue

$65.2B

FY 2025

Net Income

$20.6B

FY 2025

Free Cash Flow

—

FY 2025

Net Margin

31.7%

Insider Net (180d)

-$15.8M

0 buys / 2 sales

CEO Pay Accountability

CEO comp as % of net income

0.00%

For every $1,000 of profit, $0.04 flows to the CEO.

CEO comp as % of buybacks

0.02%

CEO comp equals 0.2‰ of cash returned to shareholders via buybacks.

5-year history · USD

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	Trend
Revenue	$65.2B	$45.0B	$34.1B	$28.5B	$28.3B
Gross Profit	—	—	—	—	—	—
Operating Income	—	—	—	—	—	—
Net Income	$20.6B	$10.6B	$5.2B	$6.2B	$5.6B
Operating CF	$16.8B	$8.8B	$4.2B	$7.1B	$7.3B
Capex	—	—	—	—	—	—
Free Cash Flow	—	—	—	—	—	—
Buybacks	$4.1B	$2.5B	$750.0M	$1.5B	$1.3B
Dividends	—	—	—	—	—	—

Gross Margin	—	—	—	—	—	—
Operating Margin	—	—	—	—	—	—
Net Margin	31.7%	23.5%	15.4%	21.9%	19.7%
FCF Margin	—	—	—	—	—	—
R&D / Revenue	—	—	—	25.2%	24.8%
Effective Tax	19.8%	16.5%	20.1%	8.3%	9.3%
Debt / Equity	1.54	4.09	3.47	2.77	3.57
Buybacks / FCF	—	—	—	—	—	—

FY 2025

Executive	Salary	Stock	Options	Bonus / Inc.	Other	Total
David A. RicksChair, President, and Chief Executive Officer	$1.7M	$23.3M	—	—	$10.9M	$736.2K
Anat HakimExecutive Vice President, General Counsel and Secretary	$1.0M	$6.0M	—	—	$2.7M	$162.6K
Daniel M. SkovronskyM.D., Ph.D.	$1.5M	$12.0M	—	—	$4.1M	$159.3K
Jake Van NaardenExecutive Vice President and President, Lilly Oncology and Head of Corporate Business Development	$920.2K	$4.5M	—	—	$2.1M	$72.5K
Lucas MontarceExecutive Vice President and Chief Financial Officer	$1.0M	$5.0M	—	—	$2.4M	$60.0K